These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

334 related articles for article (PubMed ID: 25108820)

  • 1. A new mechanism of allostery in a G protein-coupled receptor dimer.
    Lane JR; Donthamsetti P; Shonberg J; Draper-Joyce CJ; Dentry S; Michino M; Shi L; López L; Scammells PJ; Capuano B; Sexton PM; Javitch JA; Christopoulos A
    Nat Chem Biol; 2014 Sep; 10(9):745-52. PubMed ID: 25108820
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The structural determinants of the bitopic binding mode of a negative allosteric modulator of the dopamine D
    Draper-Joyce CJ; Michino M; Verma RK; Klein Herenbrink C; Shonberg J; Kopinathan A; Scammells PJ; Capuano B; Thal DM; Javitch JA; Christopoulos A; Shi L; Lane JR
    Biochem Pharmacol; 2018 Feb; 148():315-328. PubMed ID: 29325769
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of a Novel Class of Negative Allosteric Modulator of the Dopamine D2 Receptor Through Fragmentation of a Bitopic Ligand.
    Mistry SN; Shonberg J; Draper-Joyce CJ; Klein Herenbrink C; Michino M; Shi L; Christopoulos A; Capuano B; Scammells PJ; Lane JR
    J Med Chem; 2015 Sep; 58(17):6819-43. PubMed ID: 26258690
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structure-activity study of N-((trans)-4-(2-(7-cyano-3,4-dihydroisoquinolin-2(1H)-yl)ethyl)cyclohexyl)-1H-indole-2-carboxamide (SB269652), a bitopic ligand that acts as a negative allosteric modulator of the dopamine D2 receptor.
    Shonberg J; Draper-Joyce C; Mistry SN; Christopoulos A; Scammells PJ; Lane JR; Capuano B
    J Med Chem; 2015 Jul; 58(13):5287-307. PubMed ID: 26052807
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The E2.65A mutation disrupts dynamic binding poses of SB269652 at the dopamine D2 and D3 receptors.
    Verma RK; Abramyan AM; Michino M; Free RB; Sibley DR; Javitch JA; Lane JR; Shi L
    PLoS Comput Biol; 2018 Jan; 14(1):e1005948. PubMed ID: 29337986
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The action of a negative allosteric modulator at the dopamine D
    Draper-Joyce CJ; Verma RK; Michino M; Shonberg J; Kopinathan A; Klein Herenbrink C; Scammells PJ; Capuano B; Abramyan AM; Thal DM; Javitch JA; Christopoulos A; Shi L; Lane JR
    Sci Rep; 2018 Jan; 8(1):1208. PubMed ID: 29352161
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dopamine D2 Receptors Dimers: How can we Pharmacologically Target Them?
    Carli M; Kolachalam S; Aringhieri S; Rossi M; Giovannini L; Maggio R; Scarselli M
    Curr Neuropharmacol; 2018 Jan; 16(2):222-230. PubMed ID: 28521704
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The First Negative Allosteric Modulator for Dopamine D
    Rossi M; Fasciani I; Marampon F; Maggio R; Scarselli M
    Mol Pharmacol; 2017 Jun; 91(6):586-594. PubMed ID: 28265019
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacological Characterization of the Imipridone Anticancer Drug ONC201 Reveals a Negative Allosteric Mechanism of Action at the D
    Free RB; Cuoco CA; Xie B; Namkung Y; Prabhu VV; Willette BKA; Day MM; Sanchez-Soto M; Lane JR; Laporte SA; Shi L; Allen JE; Sibley DR
    Mol Pharmacol; 2021 Oct; 100(4):372-387. PubMed ID: 34353882
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Allosteric communication between protomers of dopamine class A GPCR dimers modulates activation.
    Han Y; Moreira IS; Urizar E; Weinstein H; Javitch JA
    Nat Chem Biol; 2009 Sep; 5(9):688-95. PubMed ID: 19648932
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ago-allosteric modulation and other types of allostery in dimeric 7TM receptors.
    Schwartz TW; Holst B
    J Recept Signal Transduct Res; 2006; 26(1-2):107-28. PubMed ID: 16595341
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular alliance-from orthosteric and allosteric ligands to dualsteric/bitopic agonists at G protein coupled receptors.
    Mohr K; Schmitz J; Schrage R; Tränkle C; Holzgrabe U
    Angew Chem Int Ed Engl; 2013 Jan; 52(2):508-16. PubMed ID: 23225228
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bitopic Ligands and Metastable Binding Sites: Opportunities for G Protein-Coupled Receptor (GPCR) Medicinal Chemistry.
    Fronik P; Gaiser BI; Sejer Pedersen D
    J Med Chem; 2017 May; 60(10):4126-4134. PubMed ID: 28140580
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multivalent approaches and beyond: novel tools for the investigation of dopamine D2 receptor pharmacology.
    Kopinathan A; Scammells PJ; Lane JR; Capuano B
    Future Med Chem; 2016 Jul; 8(11):1349-72. PubMed ID: 27357619
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Allosteric mechanisms within the adenosine A2A-dopamine D2 receptor heterotetramer.
    Ferré S; Bonaventura J; Tomasi D; Navarro G; Moreno E; Cortés A; Lluís C; Casadó V; Volkow ND
    Neuropharmacology; 2016 May; 104():154-60. PubMed ID: 26051403
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Allosteric properties of G protein-coupled receptor oligomers.
    Springael JY; Urizar E; Costagliola S; Vassart G; Parmentier M
    Pharmacol Ther; 2007 Sep; 115(3):410-8. PubMed ID: 17655934
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Role of Lipids in Allosteric Modulation of Dopamine D
    Żuk J; Bartuzi D; Miszta P; Kaczor AA
    Molecules; 2022 Feb; 27(4):. PubMed ID: 35209123
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular mechanisms of bitopic ligand engagement with the M1 muscarinic acetylcholine receptor.
    Keov P; López L; Devine SM; Valant C; Lane JR; Scammells PJ; Sexton PM; Christopoulos A
    J Biol Chem; 2014 Aug; 289(34):23817-37. PubMed ID: 25006252
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Orthosteric/allosteric bitopic ligands: going hybrid at GPCRs.
    Valant C; Sexton PM; Christopoulos A
    Mol Interv; 2009 Jun; 9(3):125-35. PubMed ID: 19592673
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel mechanism of G protein-coupled receptor functional selectivity. Muscarinic partial agonist McN-A-343 as a bitopic orthosteric/allosteric ligand.
    Valant C; Gregory KJ; Hall NE; Scammells PJ; Lew MJ; Sexton PM; Christopoulos A
    J Biol Chem; 2008 Oct; 283(43):29312-21. PubMed ID: 18723515
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.